ARTICLE | Finance
OnCore performance
Ex-Pharmasset execs line up money, assets in OnCore to tackle HBV
September 15, 2014 7:00 AM UTC
After helping to develop blockbuster HCV drug Sovaldi sofosbuvir, a team of ex-Pharmasset Inc. executives now have lined up money and assets in OnCore Biopharma Inc. and have set their eyes on a new prize: a cure for chronic HBV.
The OnCore team includes CEO Patrick Higgins, former EVP of commercial at Pharmasset; and CSO and head of R&D Michael Sofia, who was SVP of chemistry at Pharmasset and then at Gilead Sciences Inc. (NASDAQ:GILD). Gilead paid $11 billion for Pharmasset in 2011 and proceeded to turn Sovaldi into an overnight blockbuster after it was launched in December...